| Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients - cognitive impairment in urticaria patients | Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients - cognitive impairment in urticaria patients | EUCTR2005-002582-37-DE |
| Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers. | A single dose, randomized, open-label, pharmacokinetic study of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule in a 2 way crossover comparison against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers. | ACTRN12619001352190 |
| Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule conducted under fasting conditions in healthy male volunteers. | A single dose, randomized, open-label, pharmacokinetic study of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule in a 2 way crossover comparison against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers. | ACTRN12619001492145 |
| Comparative assessment of the absorption of a generic formulation of 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers. | A single dose, randomized, open-label, pharmacokinetic study of a generic formulation of 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule in a 2 way crossover comparison against the innovator 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers. | ACTRN12619001501134 |
